Conversely, high-throughput targeting this pathway with a small-molecule survivin suppressant currently in the clinic (YM155) selectively synergized with doxorubicin, and restored apoptosis in heterogeneous breast cancer cell types. This evidence concerns the gene BIRC5 and breast cancer.